36 completed, 4 terminated, 1 suspended. 33 Phase 2, 7 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Completed 30, Terminated 3 |
| Phase 1 | 7 | Completed 6, Terminated 1 |
| Phase 3 | 3 | Completed 2, Suspended 1 |
Follow enzastaurin: new trials by email Literature Review of enzastaurin trials Research Report on enzastaurin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome. Enzastaurin, Placebo - Vascular Ehlers-Danlos Syndrome | Phase 3 | Suspended | Aytu BioPharma, Inc. | 260 | 2025-01-01 | 2024-03-08 |
| A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma Enzastaurin - Solid Tumor, Lymphoma, Malignant | Phase 1 | Completed | Eli Lilly and Company | 26 | 2011-11-01 | 2020-10-12 |
| A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin warfarin, enzastaurin - Solid Tumor, Lymphoma, Malignant | Phase 1 | Completed | Eli Lilly and Company | 13 | 2011-08-01 | 2020-07-01 |
| A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma Enzastaurin - Cutaneous T-Cell Lymphoma | Phase 2 | Completed | Eli Lilly and Company | 25 | 2008-09-01 | 2020-10-19 |
| A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma Enzastaurin - Waldenstrom's Macroglobulinemia, Multiple Myeloma | Phase 2 | Completed | Eli Lilly and Company | 56 | 2008-07-01 | 2020-09-03 |
| A Study for Participants With Metastatic Renal Cell Carcinoma Enzastaurin, Sunitinib, Placebo - Metastatic Renal Cell Carcinoma | Phase 2 | Completed | Eli Lilly and Company | 17 | 2008-06-30 | 2019-09-30 |
| Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer Enzastaurin, Placebo, Leucovorin (LV) - Colorectal Cancer | Phase 2 | Completed | Eli Lilly and Company | 117 | 2008-02-01 | 2020-07-21 |
| A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers Enzastaurin, Placebo - Lung Cancer | Phase 2 | Completed | Eli Lilly and Company | 40 | 2007-12-01 | 2020-09-21 |
| Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas enzastaurin, bevacizumab, Enzyme-inducing antiepileptic drugs (EIAED) - Recurrent Glioblastoma | Phase 2 | Completed | Eli Lilly and Company | 81 | 2007-11-01 | 2020-09-24 |
| A Study for Patients With Non-Hodgkin's Lymphomas enzastaurin - T-Cell Lymphoma, B-Cell Lymphoma | Phase 2 | Completed | Eli Lilly and Company | 57 | 2007-11-01 | 2020-10-19 |
| Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer Enzastaurin, Bevacizumab, Paclitaxel - Breast Cancer | Phase 2 | Terminated | Eli Lilly and Company | 2 | 2007-11-01 | 2020-09-24 |
| Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy enzastaurin, pemetrexed, carboplatin - Non-small Cell Lung Cancer | Phase 2 | Completed | Eli Lilly and Company | 40 | 2007-10-01 | 2021-05-13 |
| Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma Enzastaurin 500 milligram (mg) Once Daily (QD), Enzastaurin 250 mg Twice Daily (BID) - Glioblastoma Multiforme | Phase 2 | Completed | Eli Lilly and Company | 60 | 2007-10-01 | 2019-04-05 |
| Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer enzastaurin, placebo, pemetrexed - Non-small Cell Lung Cancer | Phase 2 | Completed | Eli Lilly and Company | 160 | 2007-09-01 | 2020-07-01 |
| Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo enzastaurin, pemetrexed, cisplatin - Lung Cancer | Phase 2 | Terminated | Eli Lilly and Company | 35 | 2007-09-01 | 2020-11-05 |
| A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients enzastaurin, placebo, docetaxel - Prostate Cancer | Phase 2 | Completed | Eli Lilly and Company | 108 | 2007-06-01 | 2020-11-06 |
| A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only enzastaurin, rituximab, cyclophosphamide - Lymphoma | Phase 2 | Completed | Eli Lilly and Company | 101 | 2007-05-01 | 2020-07-21 |
| A Study of Enzastaurin in Participants With Follicular Lymphoma Enzastaurin - Lymphoma, Follicular | Phase 2 | Completed | Eli Lilly and Company | 66 | 2007-05-01 | 2018-11-05 |
| A Study of Enzastaurin in Patients With Leukemia enzastaurin - Leukemia, Lymphocytic | Phase 1 | Completed | Eli Lilly and Company | 18 | 2007-05-01 | 2009-03-19 |
| A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer enzastaurin, erlotinib - Non-Small Cell Lung Cancer, Malignant Solid Tumor | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 65 | 2007-05-01 | 2021-05-13 |
Showing 20 of 41. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Glioblastoma (4) · Neoplasms (4) · Breast Neoplasms (3) · Glioma (3) · Lymphoma (3) · Brain Neoplasms (2) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Lymphoma, Non-Hodgkin (2) · Ovarian Neoplasms (2) · Prostatic Neoplasms (2) · Carcinoma (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1)
Eli Lilly and Company (39) · Aytu BioPharma, Inc. (1) · National Cancer Institute (NCI) (1)
United States (29) · Germany (12) · France (11) · Italy (8) · Poland (6) · Australia (5) · Belgium (4) · Mexico (4) · Spain (4) · Austria (3) · Denmark (3) · Netherlands (3) · Sweden (3) · Brazil (2) · Canada (2)
Joohee Sul, M.D. (1)
PMID 20124186, PMID 20369375, PMID 20814815, PMID 21102260, PMID 21649541, PMID 22160298, PMID 22213153, PMID 23435622, PMID 23770158, PMID 25098701, PMID 26643807, PMID 26942463, PMID 27217449